Anne Vallerga PhD, CEO
Colby Pharma President; UC-Berkeley Bio Executive Institute, HAAS School of Business; Stanford Med IRB; UCSF Pharmaceutical Chemistry
Mark Tolpin MD, CMO
Prior Medical Director Celgene, PharmaNet, DuPont, VP@SangStat, BMS, Sandoz (Novartis)
Vision: To provide safe, ultra-low dose, rapid and effective allergy disease control and cure for people who suffer from allergies.
Mission: To standardize, manufacture, and out-license an Intralymphnode Allergen ImmunoTherapy (IL-AIT) system with validated IL-AIT allergens for allergy disease control.
Value: Rapid allergic disease control for allergic rhinitis enabled with 3 low dose (1/1000) intralymphnode allergen treatments in 2 months & 100% patient compliance and no adverse events (compared to 80 high dose standard of care under the skin allergen treatments in 60 months & 15% patient compliance with risk of an adverse event)
Immunotherapies for Allergic Disease Control
Scott Jenkins PhD, MBA, President
CEO Positions - Alchemist Ventures, Certainty Health, BioSign; Sr Exec Positions @ Applied Biosystems, Dell, IBM, Apple, Sandoz (Novartis)
Laird Cagan MBA, CFO
CFO Founder Cagan, McAfee Capital Partners; Investor and Entrepreneur 10 public companies; SF Chair Tiger 21 &YPO; Prior M&A Investment Banking: Drexel Burnham Lambert & Goldman, Sachs & Co.